Cargando…

(89)Zr-immuno-PET using the anti-LAG-3 tracer [(89)Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC

PURPOSE: Although lymphocyte activation gene-3 (LAG-3) directed therapies demonstrate promising clinical anti-cancer activity, only a subset of patients seems to benefit and predictive biomarkers are lacking. Here, we explored the potential use of the anti-LAG-3 antibody tracer [(89)Zr]Zr-BI 754111...

Descripción completa

Detalles Bibliográficos
Autores principales: Miedema, Iris H.C., Huisman, Marc C., Zwezerijnen, Gerben J.C., Grempler, Rolf, Pitarch, Alejandro Perez, Thiele, Andrea, Hesse, Raphael, Elgadi, Mabrouk, Peltzer, Alexander, Vugts, Danielle J., van Dongen, Guus A.M.S., de Gruijl, Tanja D., Menke-van der Houven van Oordt, C. Willemien, Bahce, Idris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199858/
https://www.ncbi.nlm.nih.gov/pubmed/36859619
http://dx.doi.org/10.1007/s00259-023-06164-w
_version_ 1785045019844935680
author Miedema, Iris H.C.
Huisman, Marc C.
Zwezerijnen, Gerben J.C.
Grempler, Rolf
Pitarch, Alejandro Perez
Thiele, Andrea
Hesse, Raphael
Elgadi, Mabrouk
Peltzer, Alexander
Vugts, Danielle J.
van Dongen, Guus A.M.S.
de Gruijl, Tanja D.
Menke-van der Houven van Oordt, C. Willemien
Bahce, Idris
author_facet Miedema, Iris H.C.
Huisman, Marc C.
Zwezerijnen, Gerben J.C.
Grempler, Rolf
Pitarch, Alejandro Perez
Thiele, Andrea
Hesse, Raphael
Elgadi, Mabrouk
Peltzer, Alexander
Vugts, Danielle J.
van Dongen, Guus A.M.S.
de Gruijl, Tanja D.
Menke-van der Houven van Oordt, C. Willemien
Bahce, Idris
author_sort Miedema, Iris H.C.
collection PubMed
description PURPOSE: Although lymphocyte activation gene-3 (LAG-3) directed therapies demonstrate promising clinical anti-cancer activity, only a subset of patients seems to benefit and predictive biomarkers are lacking. Here, we explored the potential use of the anti-LAG-3 antibody tracer [(89)Zr]Zr-BI 754111 as a predictive imaging biomarker and investigated its target specific uptake as well as the correlation of its tumor uptake and the tumor immune infiltration. METHODS: Patients with head and neck (N = 2) or lung cancer (N = 4) were included in an imaging substudy of a phase 1 trial with BI 754091 (anti-PD-1) and BI 754111 (anti-LAG-3). After baseline tumor biopsy and [(18)F]FDG-PET, patients were given 240 mg of BI 754091, followed 8 days later by administration of [(89)Zr]Zr-BI 754111 (37 MBq, 4 mg). PET scans were performed 2 h, 96 h, and 144 h post-injection. To investigate target specificity, a second tracer administration was given two weeks later, this time with pre-administration of 40 (N = 3) or 600 mg (N = 3) unlabeled BI 754111, followed by PET scans at 96 h and 144 h post-injection. Tumor immune cell infiltration was assessed by immunohistochemistry and RNA sequencing. RESULTS: Tracer uptake in tumors was clearly visible at the 4-mg mass dose (tumor-to-plasma ratio 1.63 [IQR 0.37-2.89]) and could be saturated by increasing mass doses (44 mg: 0.67 [IQR 0.50–0.85]; 604 mg: 0.56 [IQR 0.42–0.75]), demonstrating target specificity. Tumor uptake correlated to immune cell-derived RNA signatures. CONCLUSIONS: [(89)Zr]Zr-BI-754111 PET imaging shows favorable technical and biological characteristics for developing a potential predictive imaging biomarker for LAG-3-directed therapies. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03780725. Registered 19 December 2018 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-023-06164-w.
format Online
Article
Text
id pubmed-10199858
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-101998582023-05-22 (89)Zr-immuno-PET using the anti-LAG-3 tracer [(89)Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC Miedema, Iris H.C. Huisman, Marc C. Zwezerijnen, Gerben J.C. Grempler, Rolf Pitarch, Alejandro Perez Thiele, Andrea Hesse, Raphael Elgadi, Mabrouk Peltzer, Alexander Vugts, Danielle J. van Dongen, Guus A.M.S. de Gruijl, Tanja D. Menke-van der Houven van Oordt, C. Willemien Bahce, Idris Eur J Nucl Med Mol Imaging Original Article PURPOSE: Although lymphocyte activation gene-3 (LAG-3) directed therapies demonstrate promising clinical anti-cancer activity, only a subset of patients seems to benefit and predictive biomarkers are lacking. Here, we explored the potential use of the anti-LAG-3 antibody tracer [(89)Zr]Zr-BI 754111 as a predictive imaging biomarker and investigated its target specific uptake as well as the correlation of its tumor uptake and the tumor immune infiltration. METHODS: Patients with head and neck (N = 2) or lung cancer (N = 4) were included in an imaging substudy of a phase 1 trial with BI 754091 (anti-PD-1) and BI 754111 (anti-LAG-3). After baseline tumor biopsy and [(18)F]FDG-PET, patients were given 240 mg of BI 754091, followed 8 days later by administration of [(89)Zr]Zr-BI 754111 (37 MBq, 4 mg). PET scans were performed 2 h, 96 h, and 144 h post-injection. To investigate target specificity, a second tracer administration was given two weeks later, this time with pre-administration of 40 (N = 3) or 600 mg (N = 3) unlabeled BI 754111, followed by PET scans at 96 h and 144 h post-injection. Tumor immune cell infiltration was assessed by immunohistochemistry and RNA sequencing. RESULTS: Tracer uptake in tumors was clearly visible at the 4-mg mass dose (tumor-to-plasma ratio 1.63 [IQR 0.37-2.89]) and could be saturated by increasing mass doses (44 mg: 0.67 [IQR 0.50–0.85]; 604 mg: 0.56 [IQR 0.42–0.75]), demonstrating target specificity. Tumor uptake correlated to immune cell-derived RNA signatures. CONCLUSIONS: [(89)Zr]Zr-BI-754111 PET imaging shows favorable technical and biological characteristics for developing a potential predictive imaging biomarker for LAG-3-directed therapies. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03780725. Registered 19 December 2018 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-023-06164-w. Springer Berlin Heidelberg 2023-03-02 2023 /pmc/articles/PMC10199858/ /pubmed/36859619 http://dx.doi.org/10.1007/s00259-023-06164-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Miedema, Iris H.C.
Huisman, Marc C.
Zwezerijnen, Gerben J.C.
Grempler, Rolf
Pitarch, Alejandro Perez
Thiele, Andrea
Hesse, Raphael
Elgadi, Mabrouk
Peltzer, Alexander
Vugts, Danielle J.
van Dongen, Guus A.M.S.
de Gruijl, Tanja D.
Menke-van der Houven van Oordt, C. Willemien
Bahce, Idris
(89)Zr-immuno-PET using the anti-LAG-3 tracer [(89)Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
title (89)Zr-immuno-PET using the anti-LAG-3 tracer [(89)Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
title_full (89)Zr-immuno-PET using the anti-LAG-3 tracer [(89)Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
title_fullStr (89)Zr-immuno-PET using the anti-LAG-3 tracer [(89)Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
title_full_unstemmed (89)Zr-immuno-PET using the anti-LAG-3 tracer [(89)Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
title_short (89)Zr-immuno-PET using the anti-LAG-3 tracer [(89)Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
title_sort (89)zr-immuno-pet using the anti-lag-3 tracer [(89)zr]zr-bi 754111: demonstrating target specific binding in nsclc and hnscc
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199858/
https://www.ncbi.nlm.nih.gov/pubmed/36859619
http://dx.doi.org/10.1007/s00259-023-06164-w
work_keys_str_mv AT miedemairishc 89zrimmunopetusingtheantilag3tracer89zrzrbi754111demonstratingtargetspecificbindinginnsclcandhnscc
AT huismanmarcc 89zrimmunopetusingtheantilag3tracer89zrzrbi754111demonstratingtargetspecificbindinginnsclcandhnscc
AT zwezerijnengerbenjc 89zrimmunopetusingtheantilag3tracer89zrzrbi754111demonstratingtargetspecificbindinginnsclcandhnscc
AT gremplerrolf 89zrimmunopetusingtheantilag3tracer89zrzrbi754111demonstratingtargetspecificbindinginnsclcandhnscc
AT pitarchalejandroperez 89zrimmunopetusingtheantilag3tracer89zrzrbi754111demonstratingtargetspecificbindinginnsclcandhnscc
AT thieleandrea 89zrimmunopetusingtheantilag3tracer89zrzrbi754111demonstratingtargetspecificbindinginnsclcandhnscc
AT hesseraphael 89zrimmunopetusingtheantilag3tracer89zrzrbi754111demonstratingtargetspecificbindinginnsclcandhnscc
AT elgadimabrouk 89zrimmunopetusingtheantilag3tracer89zrzrbi754111demonstratingtargetspecificbindinginnsclcandhnscc
AT peltzeralexander 89zrimmunopetusingtheantilag3tracer89zrzrbi754111demonstratingtargetspecificbindinginnsclcandhnscc
AT vugtsdaniellej 89zrimmunopetusingtheantilag3tracer89zrzrbi754111demonstratingtargetspecificbindinginnsclcandhnscc
AT vandongenguusams 89zrimmunopetusingtheantilag3tracer89zrzrbi754111demonstratingtargetspecificbindinginnsclcandhnscc
AT degruijltanjad 89zrimmunopetusingtheantilag3tracer89zrzrbi754111demonstratingtargetspecificbindinginnsclcandhnscc
AT menkevanderhouvenvanoordtcwillemien 89zrimmunopetusingtheantilag3tracer89zrzrbi754111demonstratingtargetspecificbindinginnsclcandhnscc
AT bahceidris 89zrimmunopetusingtheantilag3tracer89zrzrbi754111demonstratingtargetspecificbindinginnsclcandhnscc